BioCentury | May 7, 2015
Top Story

Alexion to acquire Synageva

Synageva BioPharma Corp. (NASDAQ:GEVA) soared $107.52 (112%) to $203.39 on news that Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will acquire the company for $115 in cash and 0.6581 Alexion shares per Synageva share, or about $9 billion...
BioCentury | Jan 23, 2012
Company News

MediciNova, University of Colorado deal

...gained rights ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
BioCentury | Jan 2, 2012
Company News

Adeona management update

...Mich. Business: Autoimmune Hired: John Monahan as SVP of R&D, founder and formerly CEO of Avigen Inc....
BioCentury | Aug 22, 2011
Clinical News

Ibudilast: Phase II start

...rights to ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Jan 10, 2011
Clinical News

Ibudilast: Preliminary Phase Ib/IIa data

...rights to ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Dec 6, 2010
Clinical News

Ibudilast: Phase Ib started

...rights to ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Feb 8, 2010
Product Development

Checking the boxes in gene therapy

...GDNF) product for Parkinson's disease (PD). Coagulin B, an AAV gene therapy hemophilia B from Avigen Inc....
BioCentury | Feb 8, 2010
Company News

MediciNova management update

...Neurology Hired: Kirk Johnson as CSO, formerly VP of R&D at Avigen Inc. ; MediciNova acquired Avigen...
BioCentury | Dec 21, 2009
Finance

Ebb & Flow

...to $2.80, while Amgen lost $0.51 to $55.80 (see "Valuing Array's Sensitive Side," A10) . Avigen Inc....
...to $7.99 after shareholders of both neurology companies approved a deal for MediciNova to acquire Avigen...
Items per page:
1 - 10 of 243
BioCentury | May 7, 2015
Top Story

Alexion to acquire Synageva

Synageva BioPharma Corp. (NASDAQ:GEVA) soared $107.52 (112%) to $203.39 on news that Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will acquire the company for $115 in cash and 0.6581 Alexion shares per Synageva share, or about $9 billion...
BioCentury | Jan 23, 2012
Company News

MediciNova, University of Colorado deal

...gained rights ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
BioCentury | Jan 2, 2012
Company News

Adeona management update

...Mich. Business: Autoimmune Hired: John Monahan as SVP of R&D, founder and formerly CEO of Avigen Inc....
BioCentury | Aug 22, 2011
Clinical News

Ibudilast: Phase II start

...rights to ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Jan 10, 2011
Clinical News

Ibudilast: Preliminary Phase Ib/IIa data

...rights to ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Dec 6, 2010
Clinical News

Ibudilast: Phase Ib started

...rights to ibudilast to treat neuropathic pain and associated neurological disorders through its acquisition of Avigen Inc....
BioCentury | Feb 8, 2010
Product Development

Checking the boxes in gene therapy

...GDNF) product for Parkinson's disease (PD). Coagulin B, an AAV gene therapy hemophilia B from Avigen Inc....
BioCentury | Feb 8, 2010
Company News

MediciNova management update

...Neurology Hired: Kirk Johnson as CSO, formerly VP of R&D at Avigen Inc. ; MediciNova acquired Avigen...
BioCentury | Dec 21, 2009
Finance

Ebb & Flow

...to $2.80, while Amgen lost $0.51 to $55.80 (see "Valuing Array's Sensitive Side," A10) . Avigen Inc....
...to $7.99 after shareholders of both neurology companies approved a deal for MediciNova to acquire Avigen...
Items per page:
1 - 10 of 243